Key result
Endo-epicardial homogenization linked to ~54% lower ventricular arrhythmia recurrence vs limited endocardial ablation in ICM.
Why the study?
Catheter ablation of electrical storms for ventricular arrhythmias has shown moderate long-term efficacy in patients with ischemic cardiomyopathy.
Does endo-epicardial homogenization of the scar reduce ventricular arrhythmia recurrence compared to limited endocardial substrate ablation in patients with ischemic cardiomyopathy and electrical storms?
Cohort (n=92)
Open-label
Yes
Does endo-epicardial homogenization of the scar reduce ventricular arrhythmia recurrence compared to limited endocardial substrate ablation in patients with ischemic cardiomyopathy and electrical storms?
Hazard Ratio: 0.46 (95% CI 0.21–0.87)
Absolute Event Rate: 18.6% vs 46.9%
p-value: p=0.025
Endo-epicardial homogenization of the scar significantly improves long-term freedom from ventricular arrhythmias compared to limited endocardial ablation in patients with ischemic cardiomyopathy and electrical storms.
OBJECTIVES: This study investigated the impact on recurrences of 2 different substrate approaches for the treatment of these arrhythmias. BACKGROUND: Catheter ablation of electrical storms (ES) for ventricular arrhythmias (VAs) has shown moderate long-term efficacy in patients with ischemic cardiomyopathy. METHODS: Ninety-two consecutive patients (81% male, age 62 ± 13 years) with ischemic cardiomyopathy and ES underwent catheter ablation. Patients were treated either by confining the radiofrequency lesions to the endocardial surface with limited substrate ablation (Group 1, n = 49) or underwent endocardial and epicardial ablation of abnormal potentials within the scar (homogenization of the scar, Group 2, n = 43). Epicardial access was obtained in all Group 2 patients, whereas epicardial ablation was performed in 33% (14) of these patients. RESULTS: Mean ejection fraction was 27 ± 5. During a mean follow-up of 25 ± 10 months, the VAs recurrence rate of any ventricular tachycardia (VTs) was 47% (23 of 49 patients) in Group 1 and 19% (8 of 43 patients) in Group 2 (log-rank p = 0.006). One patient in Group 1 and 1 patient in Group 2 died at follow-up for noncardiac reasons. CONCLUSIONS: Our study demonstrates that ablation using endo-epicardial homogenization of the scar significantly increases freedom from VAs in ischemic cardiomyopathy patients.
No takes yet. Share an insight, caveat, or question.
Biase et al. (2012) conducted a cohort in Ischemic cardiomyopathy and electrical storms (n=92). Endo-epicardial homogenization of the scar vs. Limited endocardial substrate ablation was evaluated on Ventricular arrhythmia recurrence (HR 0.46, 95% CI 0.21-0.87, p=0.025). Endo-epicardial homogenization of the scar significantly reduced the risk of ventricular arrhythmia recurrence (HR 0.46) compared to limited endocardial substrate ablation in patients with ischemic cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: